Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

September 05, 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

April 24, 2025

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

News Conference News TCT 2024

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

October 29, 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

News Conference News SCAI 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

May 06, 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

April 10, 2024

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

June 09, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

October 08, 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

May 21, 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

Microclots Seen on OCT and Autopsy Can Inform COVID-19 Diagnostics, Care

News Conference News TCT 2020

Microclots Seen on OCT and Autopsy Can Inform COVID-19 Diagnostics, Care

October 26, 2020

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

News Conference News TCT 2020

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

October 22, 2020

Treating Accessory Arteries May Be Important in Renal Denervation

News Conference News TCT 2020

Treating Accessory Arteries May Be Important in Renal Denervation

October 18, 2020

FlowTriever Looks Good for Acute PE in Interim FLASH Results

News Conference News TCT 2020

FlowTriever Looks Good for Acute PE in Interim FLASH Results

October 18, 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

October 18, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.